ABL Diagnostics wins court approval to buy TEXCELL operations

ABL Diagnostics has been selected by the Évry Commercial Court to acquire TEXCELL’s assets and business operations, a move that would keep the Genopole site in Évry-Courcouronnes open and transfer 29 employees. The deal expands ABL Diagnostics’ virology, biosafety, and infectious-disease footprint while adding new scientific and operational assets.

Why it matters: - The acquisition expands ABL Diagnostics’ presence in virology, biosafety, and infectious diseases. - The deal preserves operations at Genopole Évry-Courcouronnes and keeps a specialized scientific platform in place. - ABL Diagnostics gets access to assets that could support new tools for biomedical research, biological quality control, and molecular diagnostics.

What happened: - The Évry Commercial Court selected ABL Diagnostics to acquire TEXCELL’s assets and business operations. - The decision followed an industrial plan from ABL Diagnostics focused on business continuity, expertise retention, and synergies with its existing diagnostics and infectious-disease activities. - The transaction includes the transfer of 29 employees, including 23 permanent employees and 6 apprentices or trainees.

The details: - The acquisition covers TEXCELL’s strategic assets and operations. - Commercial contracts tied to the business will continue after the transfer. - Operations will remain at the Genopole site in Évry-Courcouronnes. - ABL Diagnostics will assume accrued employee rights tied to the transferred staff, valued at €91,829.24, subject to final adjustment. - TEXCELL has expertise in viral safety, biosafety, genomic analysis, immunological monitoring, and services for biotechnology and innovative therapies. - Public information shows TEXCELL France generated about €5.4 million in revenue in 2024, compared with €6.2 million in 2023 and €7.5 million in 2022. - The overall economic value of the project is estimated at about €2.9 million. - That figure includes a €225,000 purchase price for assets, split between €165,000 in intangible assets and €60,000 in tangible assets. - The deal also includes €30,000 excluding VAT for inventories. - ABL Diagnostics will reconstitute security deposits of about €100,000. - The company will assume lease financing agreements tied to operational equipment, including future lease payments of €531,792.74, subject to final adjustment. - The project includes an industrial and technological investment program estimated at €930,000. - Working capital needs are estimated at €1 million to support the acquired activities. - ABL Diagnostics said the transaction is financed from the group’s available financial resources. - The accepted offer’s terms are set out in documents filed with the Évry Commercial Court. - ABL Diagnostics plans to recruit about five additional employees to strengthen scientific activities at the site.

Between the lines: - The deal continues ABL Diagnostics’ strategic ties with the Institut Pasteur ecosystem, following the company’s HPV RNA-Seq genotyping project with Institut Pasteur in Paris. - TEXCELL’s scientific base is historically linked to the Institut Pasteur, which makes the acquisition a fit with ABL Diagnostics’ focus on innovation, virology, and infectious diseases. - TEXCELL’s capabilities in viral safety, biological control, cell culture, viral characterization, and biosafety complement ABL Diagnostics’ UltraGene, DeepChek®, and Nadis® platforms. - The acquisition gives ABL Diagnostics an operational presence at Genopole Évry-Courcouronnes, a location the company appears to see as a platform for future growth. - The transaction also adds characterized virus banks, cell line collections, virology expertise, and biosafety infrastructure that could deepen ABL Diagnostics’ R&D pipeline.

What's next: - ABL Diagnostics said further information will follow after legal and administrative formalities are completed. - The company expects to update investors on integration plans and how the acquired activities fit into its 2026 strategic roadmap. - The press release flags the deal as inside information under EU market-abuse rules and notes that forward-looking statements carry legal and third-party approval risks.

The bottom line: - ABL Diagnostics is using a court-approved acquisition to add a specialized virology and biosafety business, keep jobs and operations in Évry, and strengthen its long-term molecular diagnostics strategy.